Filtered By:
Drug: Norvir
Vaccination: Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 270 results found since Jan 2013.
TWiV 1038: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin discusses modeling poliovirus transmission and responses in New York State, FDA approves first vaccine for pregnant individuals to prevent RSV in infants, prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, Nirmatrelvir resistance – de novo E166V/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir/ritonavir monotherapy leading to clinical and virological treatment failure, incidence of new-onset hypertension post–COVID-19: comparison with influenza, and post-acute sequel...
Source: This Week in Virology - MP3 Edition - August 26, 2023 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
Hospitalization Among Patients Treated With Molnupiravir: A Retrospective Study of Administrative Data
This study aimed to describe patient characteristics and health outcomes in a cohort of adult patients treated with molnupiravir in an outpatient setting in the United States.METHODS: This was a retrospective cohort study of adults identified in the HealthVerity database with a pharmacy claim for molnupiravir between December 24, 2021, and April 14, 2022. Hospitalization and health care use were assessed over the 28 days after the molnupiravir pharmacy claim.FINDINGS: Among 26,554 patients identified, 71.1% were aged ≥50 years and 58.9% were female. A total of 8794 patients (33.1%) had received at least 1 dose of the COV...
Source: Clinical Therapeutics - August 19, 2023 Category: Drugs & Pharmacology Authors: Girish Prajapati Amar Das Yezhou Sun Eileen Fonseca Source Type: research
TWiV 1036: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin discusses Florida local transmission of dengue cases reported in Broward and Miami-Dade counties, infants admitted to US intensive care units for RSV infection during the 2022 seasonal peak, long-term risk of death and readmission after hospital admission with COVID-19 among older adults, safety profile and clinical and virological outcomes of Nirmatrelvir-Ritonavir treatment in patients with advanced chronic kidney disease and COVID-19, Fluvoxamine vs placebo for outpatients with symptomatic COVID-19, the effect of corticosteroids, antibiotics, and anticoagulants on the developme...
Source: This Week in Virology - MP3 Edition - August 19, 2023 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
Clinical outcomes of COVID-19 in Mycosis Fungoides and Sezary Syndrome
CONCLUSION: Patients with MF/SS do not necessarily have worse COVID-19 outcomes compared to the general population.PMID:37517402 | DOI:10.1159/000531831
Source: Acta Haematologica - July 30, 2023 Category: Hematology Authors: Ilana Levy Yurkovski Lior Rokach Guy Melamed Hillel Alapi Sivan Gazit Tal Patalon Tamar Tadmor Source Type: research
TWiV 1022: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin discusses autochthonous leprosy in the United States, a systematic review to identify novel clinical characteristics of Mpox virus infection and therapeutic and preventive strategies to combat the virus, two-year duration of immunity of inactivated poliovirus vaccine, evaluation of novel oral polio vaccine type 2 SIA impact in a large outbreak of circulating vaccine-derived poliovirus in Nigeria, performance of rapid antigen tests to detect symptomatic and asymptomatic SARS-CoV-2 Infection, effectiveness of the COVID-19 bivalent vaccine, oral Nirmatrelvir and Ritonavir for COVID-1...
Source: This Week in Virology - MP3 Edition - July 8, 2023 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
Oral Nirmatrelvir and Ritonavir for Covid-19 in Vaccinated, Non-Hospitalized Adults, Ages 18-50 Years
CONCLUSION: NMV-r use in vaccinated adults aged 18-50, especially with serious comorbidities, was associated with reduced all-cause hospital visits, hospitalization, and mortality in the first 30 days of Covid-19 illness. However, NMR-r in patients without significant comorbidities or with only asthma/COPD had no association of benefit. Therefore, identifying high-risk patients should be a priority and avoid over-prescription should be avoided.PMID:37387690 | DOI:10.1093/cid/ciad400
Source: Cancer Control - June 30, 2023 Category: Cancer & Oncology Authors: Jeremy Samuel Faust Ashish Kumar Jui Shah Sumanth Khadke Sourbha S Dani Sarju Ganatra Paul E Sax Source Type: research
TWiV 1018: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin discusses the CDC vaccine advisory group recommending the newly approved RSV vaccines, association of culturable-virus detection and household transmission of SARS-CoV-2, prevention of COVID-19 following a single intramuscular administration of Adintrevimab, real-world effectiveness of Nirmatrelvir/Ritonavir on COVID-19, and COVID-19 convalescent plasma outpatient therapy to prevent outpatient hospitalization. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode CDC vaccine advisory group recommends RSV vaccines Ass...
Source: This Week in Virology - MP3 Edition - June 24, 2023 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
Paxlovid for Treating COVID-19 Patients: A Case-Control Study From Two Hospitals in the Eastern Province of Saudi Arabia
Conclusion This study suggests that Paxlovid is highly effective in reducing the risk of severe COVID-19 or mortality. However, larger studies with better qualities are needed for a full assessment of the role of Paxlovid in COVID-19 management in Saudi Arabia.PMID:37337482 | PMC:PMC10277155 | DOI:10.7759/cureus.39234
Source: Cancer Control - June 20, 2023 Category: Cancer & Oncology Authors: Ali Alsaeed Abdullah Alkhalaf Ali Alomran Walaa Alsfyani Fadhel Alhaddad Mousa J Alhaddad Source Type: research
TWiV 1016: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin discusses surveillance to track progress toward poliomyelitis eradication, genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3, evaluation of Oseltamivir used to prevent hospitalization in outpatients with Influenza, viral emissions into the air and environment after SARS-CoV-2 human challenge, has COVID-19 threatened routine childhood vaccination, successful treatment of persistent symptomatic COVID-19 infection with extended duration Nirmatrelvir/Ritonavir, anemia as a risk factor for disease progression in patients admitted for COVID-19, impact of...
Source: This Week in Virology - MP3 Edition - June 17, 2023 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
TWiV 1014: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin discusses estimates of SARS-CoV-2 seroprevalence and incidence of primary SARS-CoV-2 infections among blood donors, by COVID-19 vaccination status, smart thermometer–based participatory surveillance to discern the role of children in household viral transmission during the COVID-19 pandemic, COVID-19 vaccine mandates, changing severity and epidemiology of adults hospitalized with COVID-19 in the United States after introduction of COVID-19 vaccines, effectiveness of COVID-19 treatment with Nirmatrelvir–Ritonavir or Molnupiravir among U.S. veterans, national trends in anticoagu...
Source: This Week in Virology - MP3 Edition - June 10, 2023 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes
CONCLUSION: Nirmatrelvir-ritonavir was effective in reducing 30-day hospitalization and death. Molnupiravir was associated with a benefit for 30-day mortality but not hospitalization. Further reductions in mortality from 31 to 180 days were observed with both antivirals.PRIMARY FUNDING SOURCE: U.S. Department of Veterans Affairs.PMID:37276589 | DOI:10.7326/M22-3565
Source: Annals of Internal Medicine - June 5, 2023 Category: Internal Medicine Authors: Kristina L Bajema Kristin Berry Elani Streja Nallakkandi Rajeevan Yuli Li Pradeep Mutalik Lei Yan Francesca Cunningham Denise M Hynes Mazhgan Rowneki Amy Bohnert Edward J Boyko Theodore J Iwashyna Matthew L Maciejewski Thomas F Osborne Elizabeth M Viglian Source Type: research
